Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New inhaled drug RCS-21 put to the test in healthy volunteers

NCT ID NCT06752122

First seen Nov 20, 2025 · Last updated May 23, 2026 · Updated 32 times

Summary

This early-stage study tests whether a single inhaled dose of RCS-21 is safe and tolerable in 24 healthy adults aged 18 to 64. Participants receive one dose and are closely monitored for side effects. The study does not aim to treat any disease, but to gather important safety and drug-level information for future research.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM)

    RECRUITING

    Hanover, 30625, Germany

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.